0Z2 Stock Chart & Stats
€2.02
<€0.01(0.23%)
At close: 4:00 PM EDT
€2.02
<€0.01(0.23%)
Day’s Range― - ―
52-Week Range€0.96 - €2.84
Previous CloseN/A
Volume0.00
Average Volume (3M)83.00
Market Cap
€186.32M
Enterprise Value€83.52M
Total Cash (Recent Filing)€172.80M
Total Debt (Recent Filing)€32.76M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 10, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding111,656,920
10 Day Avg. Volume200
30 Day Avg. Volume83
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.24
Price to Sales (P/S)7.63
P/FCF Ratio-0.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.48Price Target Upside72.29% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)-0.53
Revenue Forecast (FY)€7.69M
Bulls Say, Bears Say
Bulls Say
Genentech Licensing Validates AL050The Genentech agreement provides immediate non-dilutive funding while transferring development, regulatory, manufacturing, and commercialization responsibilities to an experienced partner. It also preserves substantial milestone and royalty participation, creating longer-term economic potential from AL050 without bearing the full development burden.
Partner-led Development Reduces Execution BurdenHaving Genentech assume major downstream responsibilities can reduce Alector’s operating and capital requirements for AL050 while adding a potentially stronger commercialization platform. This structure allows Alector to retain economic exposure and focus resources on its remaining immuno-neurology pipeline.
Debt Retirement Improves FlexibilityRetiring the Hercules Capital loan removes a defined debt obligation and associated financing charges, improving balance-sheet flexibility even though broader financial pressure remains. Lower debt commitments can give management more discretion in prioritizing research, partnerships, and remaining clinical programs.
Bears Say
Severe Profitability DeteriorationThe sharp revenue decline alongside an extremely negative net margin indicates that Alector lacks a stable earnings base and remains dependent on collaboration economics or future pipeline success. Deeply negative gross profit also suggests that current revenue is not translating into sustainable operating support.
Heavy Ongoing Cash BurnCash outflows of roughly $208 million in both operating and free cash flow show that the company is consuming substantial resources to sustain its activities. Persistent cash burn can increase reliance on partnerships, financing, or asset monetization and may constrain the pace of future clinical investment.
Pipeline And Partnership SetbacksThe failed Phase 3 trial, discontinued Alzheimer’s study, and pending loss of GSK materially weaken confidence in the established progranulin-focused pipeline. These setbacks reduce external validation and leave Alector needing successful replacement programs or partnerships to rebuild development momentum.
Alector News
0Z2 FAQ
What was Alector Inc’s price range in the past 12 months?
Alector Inc lowest stock price was €0.95 and its highest was €2.84 in the past 12 months.
What is Alector Inc’s market cap?
Alector Inc’s market cap is €186.32M.
When is Alector Inc’s upcoming earnings report date?
Alector Inc’s upcoming earnings report date is Nov 10, 2026 which is in 26 days.
How were Alector Inc’s earnings last quarter?
Alector Inc released its earnings results on Aug 06, 2026. The company reported -€0.187 earnings per share for the quarter, beating the consensus estimate of -€0.204 by €0.017.
Is Alector Inc overvalued?
According to Wall Street analysts Alector Inc’s price is currently Undervalued.
Does Alector Inc pay dividends?
Alector Inc does not currently pay dividends.
What is Alector Inc’s EPS estimate?
Alector Inc’s EPS estimate is -0.2.
How many shares outstanding does Alector Inc have?
Alector Inc has 111,656,920 shares outstanding.
What happened to Alector Inc’s price movement after its last earnings report?
Alector Inc reported an EPS of -€0.187 in its last earnings report, beating expectations of -€0.204. Following the earnings report the stock price went up 20.553%.
Which hedge fund is a major shareholder of Alector Inc?
Currently, no hedge funds are holding shares in DE:0Z2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alector Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€3.48 (72.29% Upside)
€3.48 (72.29% Upside)
Blogger Sentiment
Neutral
DE:0Z2 Sentiment 100%
Sector Average 67%
Sector Average 67%
Insider Transactions
Sold Shares
Worth €254.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.12%
12-Months-Change
Fundamentals
Return on Equity
-531.04%
Trailing 12-Months
Asset Growth
-43.09%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alector Inc
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
0Z2 Stock 12 Month Forecast
Average Price Target
€3.48
▲(72.29% Upside)